Researchers at the BMEII Imaging Research Center are currently undertaking groundbreaking studies in the use of imaging for the early detection and treatment assessment of cancer. Early results validate the use of noninvasive imaging tools for the detection of and screening for cancer. BMEII staff use full-body MRI service that measures body waves and blood flow to develop mathematical and statistical models to determine characteristics of a variety of cancers.
Our Specialists at BMEII are studying how MRI signals effect oxygen in blood and tumor tissue. Our group images human subject in a newly opened research facility with the state-of-the-art free Tesla MRI system.
The Cancer Imaging Core at BMEII aim’s is to provide imaging support develop and organize for cancer -imaging trials in collaboration with the many Tisch Cancer Center oncologists. This includes providing protocol expertise, scheduling imaging studies, and assessing tumor response in a timely manner. Tumor assessment is now provided electronically using MINT software. New imaging methods are being developed that will allow clinicians not only to see where a tumor is located in the body, but also to visualize the expression and activity of specific molecules that influence tumor behavior and/or response to therapy. This information is expected to have a major impact on cancer detection, individualized treatment, and drug development, as well as on our understanding of how cancer arises. We intend to narrow or close the gap between science and patients.
• Bachir Taouli – Professor of Radiology and Medicine/Vice-chair of Translational Research
• Mitchell Lustre – Lab Manager
• Georvhari Fletcher – Program Coordinator
• Jordan Cuevas – Clinical Research Coordinator II
• Lena Marra – Clinical Research Manager
Methods currently used within the Cancer Core:
RECIST – A standard way to measure the response of a tumor to treatment. If a study is eligible, one must choose target lesions that are easy to measure and calculate the sum of the length diameter.
Below is an example of a RECIST’s exam findings
CHESON – The evaluation of Lymphoma which Includes clinical examination, BM biopsy, CT scan and PET scan for lymphomas that are frequently hyper metabolic.
Below is an example of a Cheson Reading
Mount Sinai Hospital opens one of the first centers to study and treat people with what being called “Post-acute COVID Syndrome.”
Please click on the image to watch the 60 Minutes segment. New York, NY (November 22, 2020) — COVID-19 was initially thought to be a disease that was serious for the eldery and people with preexisting conditions. A potentially tough, but temporary respiratory illness...
Nanobiologic immunotherapy uses tiny, bioengineered material to harness immune systemNew York, NY (October 29, 2020) — A groundbreaking new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it...
Led by Robert Hirten, MD and Zahi Fayad, PhD, the study draws upon the collaborative efforts of the Mount Sinai COVID Informatics Center (MSCIC) and is open to all employees in the health system. It uses a unique phone App to administer questions and collect data from...
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19
Xueyan Mei, Hao-Chih Lee, […] Yang Yang
Nat Med (2020).
Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging
Max L. Senders, Anu E. Meerwaldt, ... Willem J. M. Mulder
Nat. Nanotechnol. 15, 398–405 (2020).